Elicera Therapeutics AB (8E8) Price & Analysis

0 Followers

8E8 Stock Chart & Stats

€0.47

€0.03(20.86%)

At close: Jan 08 4:00 PM EST

€0.47

€0.03(20.86%)

Day’s Range― - ―

52-Week Range€0.18 - €0.67

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€16.92M

Enterprise Value€84.26

Total Cash (Recent Filing)€58.13M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta0.90

Next Earnings

Nov 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.35

Shares Outstanding66,736,374

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.54

Price to Book (P/B)10.19

Price to Sales (P/S)0.00

P/FCF Ratio-11.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.04

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetThe absence of reported debt reduces refinancing and interest-rate exposure, giving Elicera greater financial flexibility than a similarly loss-making biotech with leverage. This supports resilience while programs remain in development.

High Gross-margin PotentialA high gross-margin profile could support attractive economics if Elicera converts its research programs into recurring partnerships, licenses, or approved products. This indicates that future scale may be more constrained by development costs than product-level economics.

Platform And Partnering ModelElicera's iTANK platform and engineered immunotherapy pipeline are designed for licensing, co-development, or acquisition transactions. Successful partnering could provide upfront, milestone, and royalty income without requiring the company to fund every stage alone.

Bears Say

Severe Revenue And Profitability WeaknessThe sharp revenue decline and deeply negative margins show that Elicera has not yet established meaningful commercial scale. Persistent losses leave the business dependent on successful development, partnering, or additional financing to build a sustainable revenue base.

High Cash BurnMaterially negative operating and free cash flow means Elicera is consuming substantial cash to fund operations and development. Unless revenue scales or costs fall, elevated funding needs may persist, increasing dependence on capital markets or strategic transactions.

Eroding Capital Base And Dilution RiskDeclining equity and strongly negative returns indicate that ongoing losses are eroding the capital base. Even without debt, continued cash consumption may require equity financing, creating dilution risk and reducing existing shareholders' participation in future value.

8E8 FAQ

What was Elicera Therapeutics AB’s price range in the past 12 months?

Elicera Therapeutics AB lowest stock price was €0.18 and its highest was €0.67 in the past 12 months.

What is Elicera Therapeutics AB’s market cap?

Elicera Therapeutics AB’s market cap is €16.92M.

When is Elicera Therapeutics AB’s upcoming earnings report date?

Elicera Therapeutics AB’s upcoming earnings report date is Nov 27, 2026 which is in 84 days.

How were Elicera Therapeutics AB’s earnings last quarter?

Elicera Therapeutics AB released its earnings results on Aug 28, 2026. The company reported -€0.01 earnings per share for the quarter.

Is Elicera Therapeutics AB overvalued?

According to Wall Street analysts Elicera Therapeutics AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Elicera Therapeutics AB pay dividends?

Elicera Therapeutics AB does not currently pay dividends.

What is Elicera Therapeutics AB’s EPS estimate?

Elicera Therapeutics AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Elicera Therapeutics AB have?

Elicera Therapeutics AB has 66,736,374 shares outstanding.

What happened to Elicera Therapeutics AB’s price movement after its last earnings report?

Elicera Therapeutics AB reported an EPS of -€0.01 in its last earnings report. Following the earnings report the stock price went down -2.885%.

Which hedge fund is a major shareholder of Elicera Therapeutics AB?

Currently, no hedge funds are holding shares in DE:8E8

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a Swedish immuno-oncology firm founded in Göteborg in 2014, is dedicated to the clinical development of cell and gene therapies that harness the immune system to combat cancer. Its promising pipeline features several drug candidates, including ELC-100, which is currently undergoing Phase I/II trials for neuroendocrine tumors. The company is also advancing ELC-201 and ELC-401 through preclinical development, with ELC-401 specifically targeting glioblastoma multiforme (a form of brain tumor). Furthermore, Elicera is developing ELC-301, a CAR T-cell therapy intended for the treatment of Non-Hodgkin's B-cell lymphoma. A cornerstone of their work is the iTANK technology platform, engineered to enhance the efficacy of their CAR T-cell therapies and stimulate killer T-cells to attack cancerous cells.